Efficacy and safety of intravenous anti-D immunoglobulin (Rhophylac®) in chronic immune thrombocytopenic purpura-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of intravenous anti-D immunoglobulin (Rhophylac®) in chronic immune thrombocytopenic purpura

Published:2007-08 Issue:4 Volume:12 Page:289-295
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Aledort L. M.¹,Salama A.²,Kovaleva L.³,Robak T.⁴,Newland A. C.⁵,Nugent D. J.⁶,Brenner B.⁷,Zenker O.⁸

Affiliation:

1. Mount Sinai Hospital, New York, NY, USA

2. University Clinics Charite Berlin, Germany

3. Russian Academy of Medical Sciences, Moscow, Russia

4. Medical University of Lodz Lodz, Poland

5. Barts and The London Queen Mary's School of Medicine and Dentistry, London, UK

6. Children's Hospital of Orange County (CHOC) Orange, CA, USA

7. Rambam Medical Center Haifa, Israel

8. CSL Behring Bern, Switzerland

Publisher

Informa UK Limited

Subject

Hematology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10245330701383908

Reference22 articles.

1. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy

2. Initial management of immune thrombocytopenic purpura in adults: A randomized controlled trial comparing intermittent anti-D with routine care

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of platelet phagocytosis as an in vitro predictor for therapeutic potential of RBC antibodies in murine ITP;Blood;2020-06-25

2. Treatment Algorithms in Systemic Lupus Erythematosus;Arthritis Care & Research;2015-08-26

3. Rozrolimupab, a mixture of recombinant human monoclonal anti-D antibodies, for the treatment of primary immune thrombocytopenia - a review;ISBT Science Series;2013-05-31

4. Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia;Blood;2012-11-01

5. Patient-reported treatment burden of chronic immune thrombocytopenia therapies;BMC Blood Disorders;2012-03-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3